ObsEva (OBSV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock OBSV vs. BDRX, MAAQ, RANI, MRNS, SNYR, ALLK, INKT, PASG, SCYX, and DYAIShould you be buying ObsEva stock or one of its competitors? The main competitors of ObsEva include Biodexa Pharmaceuticals (BDRX), Mana Capital Acquisition (MAAQ), Rani Therapeutics (RANI), Marinus Pharmaceuticals (MRNS), Synergy CHC (SNYR), Allakos (ALLK), MiNK Therapeutics (INKT), Passage Bio (PASG), SCYNEXIS (SCYX), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. ObsEva vs. Its Competitors Biodexa Pharmaceuticals Mana Capital Acquisition Rani Therapeutics Marinus Pharmaceuticals Synergy CHC Allakos MiNK Therapeutics Passage Bio SCYNEXIS Dyadic International Biodexa Pharmaceuticals (NASDAQ:BDRX) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment. Do insiders and institutionals believe in BDRX or OBSV? 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Comparatively, 14.4% of ObsEva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor BDRX or OBSV? In the previous week, Biodexa Pharmaceuticals had 2 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 0 mentions for ObsEva. Biodexa Pharmaceuticals' average media sentiment score of 0.93 beat ObsEva's score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Biodexa Pharmaceuticals Positive ObsEva Neutral Is BDRX or OBSV more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets Biodexa PharmaceuticalsN/A N/A N/A ObsEva N/A -416.36%-92.01% Which has more risk and volatility, BDRX or OBSV? Biodexa Pharmaceuticals has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Which has better valuation and earnings, BDRX or OBSV? Biodexa Pharmaceuticals has higher revenue and earnings than ObsEva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodexa Pharmaceuticals$470K68.41-$7.32MN/AN/AObsEvaN/AN/A-$58.38M-$0.92N/A SummaryBiodexa Pharmaceuticals beats ObsEva on 7 of the 9 factors compared between the two stocks. Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBSV vs. The Competition Export to ExcelMetricObsEvaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.94M$763.73M$5.62B$9.30BDividend YieldN/A4.84%4.25%4.03%P/E Ratio-0.111.1828.5719.58Price / SalesN/A25.52423.3593.43Price / CashN/A19.5636.0257.93Price / BookN/A6.918.135.54Net Income-$58.38M-$4.17M$3.24B$257.73M ObsEva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBSVObsEvaN/AN/AN/AN/A$7.94MN/A-0.1150Gap UpBDRXBiodexa Pharmaceuticals0.2372 of 5 stars$0.87+0.8%N/AN/A$31.38M$470K0.0020Gap DownMAAQMana Capital AcquisitionN/A$3.80+3.3%N/A+657.3%$30.88MN/A0.001RANIRani Therapeutics1.9962 of 5 stars$0.54+0.2%$7.33+1,267.4%-89.2%$30.78M$1.20M-0.54110News CoverageGap DownMRNSMarinus Pharmaceuticals2.042 of 5 stars$0.55-0.2%$3.92+613.3%-61.1%$30.32M$30.99M-0.22110SNYRSynergy CHC3.9111 of 5 stars$3.37+4.0%$10.00+196.7%N/A$29.79M$34.83M0.0040ALLKAllakos3.3283 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190INKTMiNK Therapeutics2.4996 of 5 stars$7.28+0.6%$37.50+415.5%+145.7%$28.82MN/A-2.8930News CoverageAnalyst DowngradeGap DownPASGPassage Bio2.5221 of 5 stars$0.43-6.1%$7.50+1,632.1%-67.7%$28.66MN/A-0.42130Stock SplitSCYXSCYNEXIS1.0638 of 5 stars$0.71-3.2%N/A-65.1%$28.54M$3.75M-1.2660Positive NewsDYAIDyadic International3.1371 of 5 stars$0.92-2.6%$6.00+555.4%-31.0%$28.28M$3.49M-4.587Positive NewsGap Up Related Companies and Tools Related Companies Biodexa Pharmaceuticals Alternatives Mana Capital Acquisition Alternatives Rani Therapeutics Alternatives Marinus Pharmaceuticals Alternatives Synergy CHC Alternatives Allakos Alternatives MiNK Therapeutics Alternatives Passage Bio Alternatives SCYNEXIS Alternatives Dyadic International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBSV) was last updated on 7/16/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OBSV Stock Alerts